Early meta-analyses of the first published RCTs did not show significant differences in mortality with anti-IL-6R agents, although they showed significantly lower rates of ICU transfer, IMV, and composite outcome of IMV or death, along with a lower rate of serious infections (22, 75, 76). The gene discussed is IL6R; the disease is infection.